Core Insights - LifeVantage Corporation reported a revenue of $47.6 million for the first quarter of fiscal 2026, reflecting a 0.7% increase year-over-year [5][10] - The company is focusing on the strategic acquisition of LoveBiome, which positions it as a leader in the natural GLP-1 activation and microbiome health markets [4] - The company expects revenue growth to accelerate in the second half of the fiscal year due to seasonality and the impact of the LoveBiome acquisition [15] Financial Performance - Revenue for the first quarter of fiscal 2026 was $47.6 million, a 0.7% increase from the same period in fiscal 2025 [5][10] - Gross profit was $37.8 million, representing 79.5% of revenue, slightly down from 79.9% in the previous year [6] - Net income for the first quarter was $2.2 million, or $0.17 per diluted share, compared to $1.8 million, or $0.14 per diluted share in the prior year [10][11] Expense Analysis - Commissions and incentives expense increased to $20.7 million, or 43.5% of revenue, up from 43.0% in the previous year [7] - Selling, general and administrative (SG&A) expenses were $14.9 million, or 31.2% of revenue, slightly down from 31.4% in the prior year [8] - Adjusted EBITDA for the first quarter was $3.9 million, compared to $4.4 million in the same period last year [11] Balance Sheet & Liquidity - The company used $2.3 million of cash from operations during the first three months of fiscal 2026, compared to $0.6 million in the same period of fiscal 2025 [12] - Cash and cash equivalents at September 30, 2025, were $13.1 million, down from $20.2 million at June 30, 2025 [12] Shareholder Returns - LifeVantage repurchased 44,000 common shares for approximately $0.6 million during the first quarter [13] - A cash dividend of $0.045 per common share was declared, to be paid on December 15, 2025 [14] Guidance - The company reiterated its revenue guidance for fiscal 2026 in the range of $225 million to $240 million, with adjusted EBITDA expected between $23 million and $26 million [15]

Core Viewpoint - LifeVantage Corporation will release its financial results for the first quarter ended September 30, 2025, on November 4, 2025, after market close, followed by a conference call for investors [1] Financial Results Announcement - The financial results will be announced after the stock market closes on November 4, 2025 [1] - A conference call for investors is scheduled for 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day [1] Participation Details - Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers [2] - A telephone replay will be available approximately two hours after the call and can be accessed until November 18, 2025 [2] Webcast Information - A live webcast of the conference call will be available on the Investor Relations section of the company's website [3] - The webcast will be archived for approximately 30 days [3] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health at the cellular level [4] - The company offers a range of products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [4] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah [4]

Core Insights - LifeVantage Corporation has successfully completed the acquisition of LoveBiome, enhancing its position in the direct sales and gut health market [1][2] - The acquisition allows LifeVantage to expand its product portfolio into the growing microbiome health sector and strengthen its market presence in the US, Taiwan, and Europe [2] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can activate health at the cellular level [3] - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [3] - LifeVantage operates through independent consultants who sell products and provide business opportunities to aspiring entrepreneurs [3]

Group 1 - LifeVantage Corporation will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, with CEO Steve Fife and CFO Carl Aure presenting [1][2] - The presentation is scheduled for approximately 11:00 a.m. Eastern Time and will be available via a live webcast on the company's Investor Relations website [2] - LifeVantage specializes in nutrigenomics, offering products that activate health processes at the cellular level, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [3] Group 2 - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah, focusing on health and wellness products that work with individual biology [3] - The company also provides a business opportunity for independent consultants to sell its products and promote entrepreneurship [3]

Core Insights - LifeVantage Corporation reported a strong financial performance for the fourth quarter and full fiscal year 2025, with a revenue growth of approximately 13% to $55.1 million in Q4 and 14.2% to $228.5 million for the full year [6][9][14] - The international business showed growth for the first time in nearly three years, particularly in the Asia/Pacific and Europe regions, which increased by approximately 8% [6][9] - The company has a strong balance sheet with $20.2 million in cash and no debt, positioning it well for future growth [22] Fourth Quarter Fiscal 2025 Summary - Revenue for Q4 was $55.1 million, a 12.6% increase year-over-year, with a 14.1% increase in the Americas and a 7.6% increase in Asia/Pacific & Europe [7][9] - Gross profit was $44.0 million, representing 79.9% of revenue, compared to 79.5% in Q4 fiscal 2024 [8] - Net income for Q4 was $2.0 million, or $0.15 per diluted share, up from $1.3 million, or $0.10 per diluted share in the prior year [12][9] Fiscal Year 2025 Summary - Total revenue for fiscal 2025 was $228.5 million, a 14.2% increase from $200.2 million in fiscal 2024 [14] - Gross profit for the year was $183.7 million, or 80.4% of revenue, compared to 79.3% in fiscal 2024 [15] - Net income for the year was $9.8 million, or $0.75 per diluted share, compared to $2.9 million, or $0.23 per diluted share in fiscal 2024 [19] Share Repurchase and Dividend - The company repurchased 0.3 million shares for $3.1 million during fiscal 2025, with approximately $17.3 million remaining under the current repurchase program [21] - A cash dividend of $0.045 per common share was declared, to be paid on September 16, 2025 [23] Fiscal Year 2026 Guidance - LifeVantage expects revenue in the range of $225 million to $240 million for fiscal 2026, with adjusted EBITDA of $23 million to $26 million [24]

Core Insights - LifeVantage Corporation has announced a definitive agreement to acquire LoveBiome, a direct sales company focused on microbiome health solutions, enhancing its position in the gut health market [1][3] - The acquisition aligns with LifeVantage's mission to activate optimal health processes and expand its product offerings in the growing gut health sector [1][5] - The global gut health supplement market is projected to grow from $14.4 billion in 2025 to $32.4 billion by 2035, with a robust CAGR of 8.4% [5] Company Strategy - The acquisition of LoveBiome is seen as a strategic move to enhance LifeVantage's Activation differentiation and broaden its community reach [1][5] - LifeVantage aims to leverage LoveBiome's expertise in microbiome science to complement its existing product portfolio, including the Protandim® family and MindBody GLP-1 System™ [1][5] - The integration of LoveBiome's innovative P84 product is expected to strengthen LifeVantage's offerings in gut health, which is increasingly recognized for its impact on overall wellness [1][5] Transaction Details - LifeVantage will acquire LoveBiome's critical operating assets and retain key personnel, including founder Kelly Olsen, to ensure operational continuity [3] - The acquisition is expected to close by mid-October, pending customary closing conditions and regulatory approvals [3] - The transaction is anticipated to enhance revenue growth and be accretive to Adjusted EPS and Adjusted EBITDA in the first year, with additional synergy opportunities [5]

Core Insights - LifeVantage Corporation will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York [1] - The company's President and CEO, Steve Fife, along with CFO Carl Aure, will present to investors on September 10, 2025, at approximately 1:00 p.m. Eastern Time [2] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can activate health at the cellular level [3] - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and the MindBody GLP-1 System™, among others [3] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah, with a business model that includes independent consultants selling products and sharing business opportunities [3]

Core Insights - LifeVantage Corporation will release its financial results for the fourth quarter and full fiscal year ended June 30, 2025, on September 4, 2025, after market close [1] - A conference call for investors will take place on the same day at 2:30 p.m. Mountain Time [1] Financial Results Announcement - The financial results will cover the fourth quarter and the full fiscal year ending June 30, 2025 [1] - The announcement will be made after the stock market closes on September 4, 2025 [1] Conference Call Details - Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers [2] - A telephone replay will be available approximately two hours after the call and will last until September 18, 2025 [2] Webcast Information - A live webcast of the conference call will be available on the Investor Relations section of the company's website [3] - The webcast will be archived for approximately 30 days [3] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health at the cellular level [4] - The company offers a range of products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [4] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah [4]

Core Insights - LifeVantage Corporation announced new results from its second human clinical study on the MindBody GLP-1 System™, showing significant improvements in GLP-1 levels and related health outcomes [1][2] Clinical Study Results - The average increase in GLP-1 production improved to over 200%, up from a previously reported 140% [2] - Participants experienced an average weight loss of 11 pounds within 12 weeks, with some losing up to 25 pounds [6] - There was a reported decrease in total body fat percentage of up to 9% and a decrease in visceral fat of up to 24% [6] - Participants reported a 100% weight loss from fat, not muscle, and a 6% increase in skeletal muscle [6] Behavioral Changes - 95% of participants reported decreased sugar cravings, while 89% reported decreased fast-food cravings [6] - 85% of participants indicated they now eat for health instead of emotions, and 81% reported an increased ability to resist snacking [6] - 89% of participants ate less at meals, and 86% reported feeling less hungry [6] Company Background - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health [5] - The company offers a range of products, including the MindBody GLP-1 System™, aimed at promoting optimal health at the cellular level [5]

Core Viewpoint - LifeVantage Corporation reported strong financial results for the third fiscal quarter of 2025, with a significant increase in revenue and profitability, driven by robust demand for its products and international expansion efforts [4][5]. Financial Performance - Revenue for the third quarter ended March 31, 2025, was $58.4 million, representing a 21.1% increase year-over-year. Excluding foreign currency fluctuations, revenue increased by 22.1% [5][9]. - Gross profit for the quarter was $47.3 million, or 81.0% of revenue, compared to 78.9% in the same period of fiscal 2024, attributed to a favorable product sales mix and reduced inventory costs [6]. - Adjusted EBITDA rose by 27% to $6.4 million from $5.1 million a year ago [9][12]. - Net income for the quarter was $3.5 million, or $0.26 per diluted share, compared to $1.7 million, or $0.13 per diluted share, in the prior year [11][9]. Regional Performance - Revenue in the Americas increased by 29.5%, with a notable 31.4% rise in the United States. Conversely, revenue in the Asia/Pacific & Europe region decreased by 7.2%, with a constant currency decline of approximately 4.7% [5][9]. Operational Highlights - The company launched its Evolve Compensation Plan in several Asian markets and introduced the MindBody GLP-1 System™ in multiple international regions, indicating a strategic focus on global market expansion [4]. - Active Independent Consultants increased by 6.1% to 52,000, with a 12.9% rise in the Americas, while the Asia/Pacific & Europe region saw a decline of 5.6% [32]. Balance Sheet and Liquidity - Cash and cash equivalents as of March 31, 2025, were $22.5 million, up from $16.9 million at the end of June 2024, with no debt outstanding [13]. - The company generated $10.8 million in cash from operations during the first nine months of fiscal 2025, compared to $9.6 million in the same period of fiscal 2024 [13]. Shareholder Returns - LifeVantage declared a cash dividend of $0.045 per common share, scheduled for payment on June 13, 2025 [15]. Fiscal Year Guidance - The company expects revenue for fiscal year 2025 to be in the range of $228 million to $235 million, with adjusted EBITDA guidance of $21 million to $24 million and adjusted earnings per share between $0.72 and $0.88 [16].